莱西康制药

US · LXRX #3430 按市值排名

1.52 -0.13 -7.88%

实时 - 追踪5344个代码 - 心跳于135秒前 · 2026-10-16 19:46

✦ 量化股权信号计算方式说明

增持

最近一期（2026/Q3）披露持股的机构数量增加了1家。
机构持股总比例上升了0.1个百分点。

机构持股

机构持股比例: 83.73% +0.12pp
机构数量: 169 +1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

VC/PE Fund50.55%

Mutual Fund23.82%

Hedge Fund8.20%

Individual/Insider1.46%

Private Company0.49%

Public Company0.40%

Insurance Company0.12%

Government Pension Fund0.11%

Other14.83%

主要股东截至 2026-06-30

Artal Group S.A. 49.32% · 219.46M 股

FMR 11.64% · 51.78M 股

Sessa Capital IM, L.P. 4.26% · 18.96M 股

BlackRock 3.90% · 17.35M 股

Vanguard Capital Management, LLC 2.59% · 11.54M 股

Point72 Asset Management, L.P. 1.85% · 8.25M 股

Geode Capital Management, LLC 1.40% · 6.24M 股

The Invus Group, LLC 1.23% · 5.45M 股

State Street Global Advisors 1.11% · 4.92M 股

Vanguard Portfolio Management, LLC 0.53% · 2.36M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 42次买入 · 8次卖出

姓名	职务	持股比例
Artal Group S.A.	--	49.32%
Raymond Debbane	Independent Chairperson	0.45%
Lonnel Coats	Chief Executive Officer	0.18%
Brian Crum	Senior Vice President	0.10%
Philippe Amouyal	Independent Director	0.08%
Alan Main	Executive Vice President of Innovation & Chemical Sciences	0.08%
Craig Granowitz	Senior VP & Chief Medical Officer	0.07%
Jeffrey Wade	President	0.07%
Michael Exton	Chief Executive Officer	0.07%
Christopher Sobecki	Independent Director	0.07%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-06-02	Raymond Debbane	Independent Chairperson	Derivative Exercise and Retained	+89,312	--
2026-06-02	Samuel Barker	Independent Director	Derivative Exercise and Retained	+89,312	--
2026-06-02	Philippe Amouyal	Independent Director	Derivative Exercise and Retained	+89,312	--
2026-06-02	Christopher Sobecki	Independent Director	Derivative Exercise and Retained	+89,312	--
2026-06-02	Judith Swain	Independent Director	Derivative Exercise and Retained	+89,312	--
2026-06-02	Diane Sullivan	Director	Derivative Exercise and Retained	+89,312	--
2026-06-02	Ivan H. Cheung	Director	Derivative Exercise and Retained	+89,312	--
2026-04-30	Raymond Debbane	Independent Chairperson	Other Derivative Acquisition	+35,714	--
2026-04-30	Raymond Debbane	Independent Chairperson	Other Derivative Acquisition	+43,478	$1.61
2026-04-30	Samuel Barker	Independent Director	Other Derivative Acquisition	+35,714	--
2026-04-30	Samuel Barker	Independent Director	Other Derivative Acquisition	+43,478	$1.61
2026-04-30	Philippe Amouyal	Independent Director	Other Derivative Acquisition	+35,714	--
2026-04-30	Philippe Amouyal	Independent Director	Other Derivative Acquisition	+43,478	$1.61
2026-04-30	Christopher Sobecki	Independent Director	Other Derivative Acquisition	+35,714	--
2026-04-30	Christopher Sobecki	Independent Director	Other Derivative Acquisition	+43,478	$1.61
2026-04-30	Judith Swain	Independent Director	Other Derivative Acquisition	+35,714	--
2026-04-30	Judith Swain	Independent Director	Other Derivative Acquisition	+43,478	$1.61
2026-04-30	Diane Sullivan	Director	Other Derivative Acquisition	+35,714	--
2026-04-30	Diane Sullivan	Director	Other Derivative Acquisition	+43,478	$1.61
2026-04-30	Ivan H. Cheung	Director	Other Derivative Acquisition	+35,714	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:46:20 · 仅供参考，不构成投资建议，也未考虑您的具体情况。